David A. Siegel V Tv Therapeutics Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$1.53 - $2.22 $64,719 - $93,906	-42,300 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$2.27 - $3.44 $354,574 - $537,328	-156,200 Reduced 78.69%	42,300 $96,000
Q1 2021 May 17, 2021	BUY	$1.97 - $2.89 $298,652 - $438,124	151,600 Added 323.24%	198,500 $560,000
Q4 2020 Feb 16, 2021	SELL	$1.49 - $3.1 $644,425 - $1.34 Million	-432,500 Reduced 90.22%	46,900 $87,000
Q3 2020 Nov 16, 2020	BUY	$1.7 - $2.98 $536,350 - $940,190	315,500 Added 192.5%	479,400 $849,000
Q2 2020 Aug 14, 2020	BUY	$1.74 - $3.19 $219,240 - $401,940	126,000 Added 332.45%	163,900 $369,000
Q1 2020 May 15, 2020	BUY	$1.63 - $3.75 $61,776 - $142,125	37,900 New	37,900 $72,000

243K

Ticker VTVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,483,600
Market Cap $1.21B
Description
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetran...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.